UCB (OTCMKTS:UCBJY) Rating Lowered to “Hold” at Barclays

UCB (OTCMKTS:UCBJY) was downgraded by equities researchers at Barclays from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Several other research analysts have also recently issued reports on the company. Zacks Research cut UCB from a “hold” rating to a “strong sell” rating in a research note on Thursday, June 11th. Wolfe Research upgraded shares of UCB to a “strong-buy” rating in a research note on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, UCB has a consensus rating of “Moderate Buy”.

UCB Price Performance

UCBJY opened at $150.09 on Monday. UCB has a 12 month low of $89.00 and a 12 month high of $168.76. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The stock’s 50 day moving average price is $145.71 and its 200 day moving average price is $147.35.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.